CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 65,600 shares, a growth of 45.1% from the November 30th total of 45,200 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 57,700 shares, the short-interest ratio is currently 1.1 days.

Insider Transactions at CalciMedica

In other news, Director Fred A. Middleton bought 87,744 shares of the stock in a transaction on Friday, November 1st. The stock was acquired at an average price of $3.75 per share, with a total value of $329,040.00. Following the acquisition, the director now directly owns 814,300 shares in the company, valued at approximately $3,053,625. This trade represents a 12.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric W. Roberts bought 53,333 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average price of $3.75 per share, for a total transaction of $199,998.75. Following the completion of the transaction, the insider now owns 164,706 shares in the company, valued at $617,647.50. This trade represents a 47.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 252,744 shares of company stock valued at $942,510. Corporate insiders own 41.55% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

Several large investors have recently added to or reduced their stakes in CALC. Atria Investments Inc lifted its stake in CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the period. Geode Capital Management LLC increased its stake in shares of CalciMedica by 51.2% in the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after acquiring an additional 22,525 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in CalciMedica during the third quarter worth $67,000.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a research report on Thursday, November 14th.

CalciMedica Stock Down 3.2 %

CALC traded down $0.09 during trading on Monday, reaching $2.76. 5,505 shares of the stock traded hands, compared to its average volume of 39,091. The stock’s 50-day moving average is $3.33 and its 200 day moving average is $4.02. CalciMedica has a 12 month low of $2.05 and a 12 month high of $8.38. The stock has a market capitalization of $37.21 million, a PE ratio of -2.56 and a beta of 1.25.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.